Trending
Revolutionary Shows Promise 4
Revolutionary Shows Promise 3
Revolutionary Shows Promise 1
Revolutionary aids Treatment Shows Promise
Revolutionary Cancer Treatment Shows Promise
FDA Expands Approval of Vonvendi for von Willebrand Disease, Including Pediatric Use
Child Depression Fluctuations may trigger Parent Depression not vice versa: JAMA
Indoor Air Quality and Diet Found to Regulate Inflammation in Childhood: Study Finds
How Smoking Fuels Pancreatic Cancer Growth and Worsens Outcomes: Study Finds Out
Follow Us:
November 02, 2025

Get In Touch

Colchicine Fails to Improve Outcomes in Long COVID Patients: JAMA Medicine

Colchicine Fails to Improve Outcomes in Long COVID Patients: JAMA

  • 27 October 2025
  • 5 days ago

Slow-Tempo Music Intervention Shows No Significant Benefit in Mechanically Ventilated Older Adults: JAMA Psychiatry

Slow-Tempo Music Intervention Shows No Significant Benefit in Mechanically Ventilated Older Adults: JAMA

  • 21 October 2025
  • 1 week ago

CBT-I acceptable and efficacious intervention for managing insomnia in chronic disease populations: JAMA Psychiatry

CBT-I acceptable and efficacious intervention for managing insomnia in chronic disease populations: JAMA

  • 04 October 2025
  • 4 weeks ago

JAMA Study: Hormone Therapy for Menopausal Symptoms Safe at 50-59, Raises Risks After 70 Medicine

JAMA Study: Hormone Therapy for Menopausal Symptoms Safe at 50-59, Raises Risks After 70

  • 29 September 2025
  • 1 month ago

Hormone Therapy for VMS: Safe in Women 50–59, Risky in Those 70+, Finds JAMA Study Diabetes and Endocrinology

Hormone Therapy for VMS: Safe in Women 50–59, Risky in Those 70+, Finds JAMA Study

  • 25 September 2025
  • 1 month ago

Common Nasal Spray Cuts COVID Risk by Two-Thirds in Clinical Trial Medicine

Common Nasal Spray Cuts COVID Risk by Two-Thirds in Clinical Trial

  • 09 September 2025
  • 1 month ago

Medical Bulletin 09/September/2025 Medicine News

Medical Bulletin 09/September/2025

  • 09 September 2025
  • 1 month ago

Among Diabetes Patients, SGLT2 Inhibitors Less Likely To Cause Gout Compared To Sulfonylureas: JAMA Medicine

Among Diabetes Patients, SGLT2 Inhibitors Less Likely To Cause Gout Compared To Sulfonylureas: JAMA

  • 13 July 2025
  • 3 months ago

Recent News

Madras HC grants bail to man accused of forging NE...

  • 01 November, 2025

AIIMS INI SS January 2026: 4 seats added in 2 spec...

  • 01 November, 2025

Treatment in Myocardial Infarction and Non-Obstruc...

  • 01 November, 2025

PG medical admissions 2025 commence in Bihar, chec...

  • 01 November, 2025

Assam to begin NEET PG 2025 counselling from Novem...

  • 01 November, 2025

Daily Newsletter

Get all the top stories from Blogs to keep track.